Carvacrol

Carvacrol at a Glance

Carvacrol is a monoterpenoid phenol — the dominant active of oregano and savory essential oil, and an isomer of thymol, differing only in where the hydroxyl sits on the ring.

Its laboratory record is genuinely impressive: potent antimicrobial and antibiofilm activity against a broad range of organisms, working by disrupting bacterial membranes rather than through a specific target, which makes resistance less likely.

Most human evidence, though, is for whole oregano essential oil rather than the isolated compound.

What It's Used For

Carvacrol is a monoterpenoid phenol — the dominant aromatic active of oregano essential oil, also present in savory and thyme, and a positional isomer of thymol. It gives these herbs their warm, pungent character and is one of the most-studied natural antimicrobials. The framing that matters most: almost all human evidence is for the essential oil or multi-herb blends, not for isolated carvacrol — the molecule’s own strong data are in the laboratory. Its marquee action is broad antimicrobial and anti-biofilm activity, mechanistically pinned to disruption of the microbial membrane ^{1Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →}, and its best-defined molecular pharmacology is as an agonist of the TRPV3 and TRPA1 ion channels ^{3,4Reference 3Xu H et al. · 2006Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channelsView study →Reference 4Mukaiyama M et al. · 2020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →} — which also explains why concentrated carvacrol is a sensory irritant. Its pharmacokinetics (rapid conjugation, low free-plasma levels) mean the impressive dish-level potency is best understood at mucosal and surface sites, not as a systemic drug ^{7Reference 7Dong RH et al. · 2012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}.

A genuine antimicrobial, in vitro:broad activity against bacteria and Candida, including mature biofilms, with a well-worked-out membrane mechanism and structure-activity basis in the free phenolic hydroxyl ^{1,2,13Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →Reference 2Ultee A et al. · 2002The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereusView study →Reference 13Ben Arfa A et al. · 2006Antimicrobial activity of carvacrol related to its chemical structureView study →}.

Human data are the oil, not the molecule:the closest clinical signal — a herbal blend non-inferior to rifaximin for SIBO — used oregano-oil-containing capsules, open-label, not weighed carvacrol ^{22Reference 22Chedid V et al. · 2014Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowthView study →}.

The honest headline:anti-inflammatory, antioxidant, antiparasitic and anticancer findings are preclinical, and low systemic exposure means in-vitro concentrations aren’t reached in blood ^{7Reference 7Dong RH et al. · 2012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Carvacrol’s isolate evidence is preclinical, so scores stay low by design. Each application links to its write-up.

This is carvacrol’s strongest and best-isolated evidence. It has broad activity against Gram-positive and Gram-negative bacteria and Candida, including mature biofilms that resist fluconazole, plus quorum-sensing interference and synergy with thymol ^{12,13,14,15,16Reference 12Marchese A et al. · 2018The natural plant compound carvacrol as an antimicrobial and anti-biofilm agent: mechanisms, synergies and bio-inspired anti-infective materialsView study →Reference 13Ben Arfa A et al. · 2006Antimicrobial activity of carvacrol related to its chemical structureView study →Reference 14Veldhuizen EJ et al. · 2006Structural requirements for the antimicrobial activity of carvacrolView study →Reference 15Swetha TK et al. · 2020Synergistic antimicrobial combination of carvacrol and thymol impairs single and mixed-species biofilms of Candida albicans and Staphylococcus epidermidisView study →Reference 16Miranda-Cadena K et al. · 2021In-vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilmsView study →}.

The mechanism is well worked out: carvacrol permeabilizes the cytoplasmic membrane and acts as a proton carrier, collapsing the proton-motive force and depleting ATP ^{1Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →}, and structure-activity work shows the free phenolic hydroxyl is essential for this action ^{2Reference 2Ultee A et al. · 2002The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereusView study →}.

Gap: almost entirely in-vitro or food-matrix; there is no isolated-carvacrol human infection trial, and the MICs achieved in a dish are not necessarily reached in plasma (see Pharmacokinetics) ^{1,7Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →Reference 7Dong RH et al. · 2012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Cytoplasmic-membrane permeabilization; proton-motive-force collapse	K⁺/H⁺ leak, ATP depletion → bactericidal	antimicrobial (primary)
Free phenolic hydroxyl (structure-activity)	the –OH is required for antimicrobial potency	antimicrobial SAR
TRPV3 agonist / sensitizer	Ca²⁺ influx; warm-pungent sensation, skin sensitization	sensory effectstopical irritation
TRPA1 agonist	channel activation → tight-junction opening	sensory/irritantgut epithelium
TRPM7 inhibition	channel block	ion-channel pharmacology (mechanistic)
NF-κB suppression; IL-10 induction	↓ iNOS/COX-2, ↓ NO/PGE2	anti-inflammatory
Nrf2 / antioxidant response (model-dependent)	↑ antioxidant defenses	antioxidantorgan protection

Pharmacokinetics

Carvacrol behaves like a typical volatile essential-oil phenol — rapidly absorbed, extensively conjugated, rapidly cleared, with low free systemic exposure. Glucuronidation is characterized in human liver and intestinal microsomes, with UGT1A9 the major isoform ^{7Reference 7Dong RH et al. · 2012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}, and CYP-mediated phase-I metabolism of carvacrol and thymol is also demonstrated in human liver microsomes ^{20Reference 20Dong RH et al. · 2012Identification of CYP isoforms involved in the metabolism of thymol and carvacrol in human liver microsomesView study →}. Free carvacrol in plasma is very low; the circulating pool is dominated by conjugated metabolites ^{21Reference 21Allaoua M et al. · 2018Pharmacokinetics and antimicrobial activity of a new carvacrol-based product against Campylobacter jejuniView study →}. Its high volatility adds formulation and GI losses. The practical implication: the impressive in-vitro MICs and micromolar cell-culture effects may not be reached in blood after oral dosing, so activity is most plausible at mucosal, luminal and topical surfaces (gut, mouth, skin) where local concentrations are high — not as a systemic drug.

Clinical trials

There is no completed RCT of isolated carvacrol. The human evidence is for oregano/thyme essential-oil or multi-herb preparations: an open-label comparative study found a herbal antimicrobial protocol (blends that include oregano oil) statistically non-inferior to rifaximin for normalizing SIBO breath tests ^{22Reference 22Chedid V et al. · 2014Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowthView study →} — a blend, open-label, hypothesis-generating, not confirmatory. Everything human-relevant traces to the oil, not the molecule.

Completed	Planned	Terminated	Preclinical
—(isolate); oil/blend only	—	—	Extensive

Last checked: July 2026.

Toxicity & Safety

Carvacrol is consumed in small amounts as a flavoring and is classified safe as a flavoring (JECFA/FDA/EU) — a food-additive clearance at low dietary levels, not an endorsement of supplement doses ^{11,19Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →Reference 19De Vincenzi M et al. · 2004Constituents of aromatic plants: carvacrolView study →}. In concentrated form it is a skin and mucous-membrane irritant and a documented skin sensitizer, mechanistically consistent with its TRPV3/TRPA1 agonism — undiluted oregano oil should be handled diluted ^{3,4Reference 3Xu H et al. · 2006Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channelsView study →Reference 4Mukaiyama M et al. · 2020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →}. Toxicity is dose-dependent: low doses are well tolerated in animals (adverse effects generally absent below ~50 mg/kg body weight), while high concentrations show cytotoxicity and genotoxicity in vitro and high oral doses can produce GI and hepatic effects ^{11Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →}. A 90-day oral rat study of carvacrol-dominant Origanum vulgare essential oil found no treatment-related adverse effects at the tested levels — reassuring for the oil, though not a pure-carvacrol NOAEL ^{23Reference 23Llana-Ruiz-Cabello M et al. · 2017AnimalA subchronic 90-day oral toxicity study of Origanum vulgare essential oil in ratsView study →}. Drug interactions are theoretical and low-confidence: as a UGT1A9/CYP substrate it could in principle interact with co-metabolized drugs, and its TRPA1/permeation effects might enhance absorption of co-administered agents — no human interaction data exist.

Dosage

There is no established or recommended human dose for isolated carvacrol — the figures here are research and food-additive references, not a recommendation. Its only regulatory clearance is as a low-level flavoring, at trace amounts well below toxicological thresholds ^{19Reference 19De Vincenzi M et al. · 2004Constituents of aromatic plants: carvacrolView study →}. Preclinical rodent efficacy studies commonly use ~10–80 mg/kg orally, with adverse effects generally absent below ~50 mg/kg ^{11Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →} — animal figures that do not extrapolate to people. The human clinical context uses standardized oregano-oil blend capsules of product-defined, variable carvacrol content ^{22Reference 22Chedid V et al. · 2014Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowthView study →}, not weighed carvacrol.

References

Ultee A, Kets EP, Smid EJ (1999). Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereus. Applied and Environmental Microbiology. https://pubmed.ncbi.nlm.nih.gov/10508096/
Ultee A, Bennik MH, Moezelaar R (2002). The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereus. Applied and Environmental Microbiology. https://pubmed.ncbi.nlm.nih.gov/11916669/
Xu H, et al. (2006). Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nature Neuroscience. https://pubmed.ncbi.nlm.nih.gov/16617338/
Mukaiyama M, Usui T, Nagumo Y (2020). Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activation. Journal of Biochemistry. https://pubmed.ncbi.nlm.nih.gov/32428205/
Alvarenga EM, Souza LK, Araújo TS, et al. (2016). Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/27838229/
Parnas M, et al. (2009). Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell Calcium. https://pubmed.ncbi.nlm.nih.gov/19135721/
Dong RH, Fang ZZ, Zhu LL, et al. (2012). Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrol. Xenobiotica. https://pubmed.ncbi.nlm.nih.gov/22559213/
Pastor J, García M, Steinbauer S, et al. (2015). Combinations of ascaridole, carvacrol and caryophyllene oxide against Leishmania. Acta Tropica. https://pubmed.ncbi.nlm.nih.gov/25697866/
Youssefi MR, Moghaddas E, Tabari MA, et al. (2019). In-vitro and in-vivo effectiveness of carvacrol, thymol and linalool against Leishmania infantum. Molecules. https://pubmed.ncbi.nlm.nih.gov/31151304/
Sampaio LA, Pina LTS, Serafini MR, et al. (2021). Antitumor effects of carvacrol and thymol: a systematic review. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34305611/
Mączka W, et al. (2023). Carvacrol — a natural phenolic compound with antimicrobial properties. Antibiotics (Basel). https://pubmed.ncbi.nlm.nih.gov/37237727/
Marchese A, Arciola CR, Coppo E, et al. (2018). The natural plant compound carvacrol as an antimicrobial and anti-biofilm agent: mechanisms, synergies and bio-inspired anti-infective materials. Biofouling. https://pubmed.ncbi.nlm.nih.gov/30067078/
Ben Arfa A, Combes S, Preziosi-Belloy L, et al. (2006). Antimicrobial activity of carvacrol related to its chemical structure. Letters in Applied Microbiology. https://pubmed.ncbi.nlm.nih.gov/16869897/
Veldhuizen EJ, Tjeerdsma-van Bokhoven JL, Zweijtzer C, et al. (2006). Structural requirements for the antimicrobial activity of carvacrol. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/16506847/
Swetha TK, Vikraman A, Nithya C, et al. (2020). Synergistic antimicrobial combination of carvacrol and thymol impairs single and mixed-species biofilms of Candida albicans and Staphylococcus epidermidis. Biofouling. https://pubmed.ncbi.nlm.nih.gov/33435734/
Miranda-Cadena K, Marcos-Arias C, Mateo E, et al. (2021). In-vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/34649348/
Lima Mda S, Quintans-Júnior LJ, de Santana WA, et al. (2013). Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/23220159/
Gholijani N, Gharagozloo M, Farjadian S, et al. (2016). Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophages. Journal of Immunotoxicology. https://pubmed.ncbi.nlm.nih.gov/25812626/
De Vincenzi M, et al. (2004). Constituents of aromatic plants: carvacrol. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/15567271/
Dong RH, Fang ZZ, Zhu LL, et al. (2012). Identification of CYP isoforms involved in the metabolism of thymol and carvacrol in human liver microsomes. Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/23346763/
Allaoua M, Etienne P, Noirot V, et al. (2018). Pharmacokinetics and antimicrobial activity of a new carvacrol-based product against Campylobacter jejuni. Journal of Applied Microbiology. https://pubmed.ncbi.nlm.nih.gov/29770558/
Chedid V, et al. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Global Advances in Health and Medicine. https://pubmed.ncbi.nlm.nih.gov/24891990/
Llana-Ruiz-Cabello M, Maisanaba S, Puerto M, et al. (2017). A subchronic 90-day oral toxicity study of Origanum vulgare essential oil in rats. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/28065759/